3-D Changes in DNA may Lead to a Genetic Form of Lou Gehrigs Disease

New findings reveal how a mutation, a change in the genetic code that causes neurodegeneration, alters the shape of DNA, making cells more vulnerable to stress and more likely to die.
The particular mutation, in the C9orf72 gene, is the most common cause for amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease), and frontotemporal degeneration (FTD), the second most common type of dementia in people under 65.
This research by Jiou Wang, PhD, and his colleagues at Johns Hopkins University (JHU) was published in Nature and was partially funded by the National Institutes of Health’s National Institute of Neurological Disorders and Stroke (NINDS).
Using sophisticated molecular techniques, Dr Wang and his team showed that the mutation causes changes in the three-dimensional shape of DNA. DNA is normally shaped like a twisted ladder. However, the repeating sequences can fold into G-quadruplexes, stacks of square-shaped molecules known as G-quartets. "This structure has been described as a square building with each floor representing one G-quartet, normally two to four stories high,” said Dr Wang, senior author of the paper.
Their results also showed that C9orf72 mutated DNA has profound effects on how the genetic message is processed in the cell. RNA, short for ribonucleic acid, acts as an important intermediary — a middleman — in the process that converts genetic information from DNA into functional proteins. This happens in two stages: conversion of the DNA code into RNA is called transcription. RNA then forms proteins during a process known as translation.
To read NIH's full story, click here
Related News
-
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed. -
News PSCI launches progressive position on the use of Horseshoe Crabs
A quarterly series of articles about responsible supply chain management from the PSCI. -
News Delivering on mRNA-based therapeutics: innovations in applications and packaging
Since the onset of the COVID-19 pandemic, the innovative potential of mRNA vaccines and therapeutics has raised questions regarding their manufacturing, packaging, and storage/transportation. Learn about how the pharmaceutical supply chain is meet... -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News Novavax will provide adjuvant Matrix-M for vaccine research with 3-year partnership
Novavax, developers behind the Matrix-M adjuvant, have entered into an agreement with the Bill and Melinda Gates Medical Research Institute to provide the adjuvant in preclinical vaccine research. -
News Thermo Fisher Scientific opens new steriles drug manufacturing site in Singapore
The life science service and instrument provider have opened their new Singapore-based steriles drug manufacturing facility with the goal of bringing increased development and manufacturing capabilities for critical medicines to the APAC region. -
News Medicines for All receive $18.7 million grant for expansion of global access to lifesaving medication
Funded by the Bill & Melinda Gates Foundation, the Virginia Commonwealth University-based research-related institute will use the grant to expand on its current capabilities of bringing lifesaving medications around the world, as well as working on 14 ...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance